Recommendations for the Use of Clinical Data in Premarket Notification [510(k)] Submissions

This guidance provides information for situations when clinical data may be necessary to demonstrate substantial equivalence in a 510(k) submission.

Related Keywords

,Drug Administration ,Guidance Issuing Office ,Radiological Health ,Submit Comments ,Biologics Evaluation ,Evaluating Substantial Equivalence ,Premarket Notifications ,